Golden Arrow Merger Corp.

A healthcare infrastructure focused SPAC combining the expertise of four elite investment groups

About Us

Golden Arrow Merger Corp. is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While we may pursue an acquisition opportunity in any business, industry, sector, or geography, we intend to focus our search on identifying a prospective target business in the healthcare or healthcare - related infrastructure industries in the United States and other developed countries.

Press Releases

SEC Filings

All Filings for Golden Arrow Merger Corp Available via EDGAR

View Filings

Our Team

Timothy Babich, Chief Executive Officer and Chief Financial Officer


Timothy Babich serves as our Chief Executive Officer and Chief Financial Officer. Mr. Babich founded and manages Nexxus Holdings, an investment firm primarily dedicated to managing his investments. Nexxus opportunistically invests in private and public investments. At Nexxus, in late 2020, Mr. Babich merged two Ambulatory Surgery Center software businesses, HST and Casetabs, and was personally the largest shareholder of Casetabs. The combination has created the leading modern software suite for the fast-growing ASC market. In addition, Mr. Babich was the founder and chairman of FCM Bank, a European based, online challenger bank. FCM Bank was founded in 2012 and sold in 2017 to a private European payments platform. Mr. Babich also is the co-founder of the RUNX1 Research Program, a medical foundation dedicated to finding a cure for an inherited predisposition to leukemia. In 2006, Mr. Babich founded and was CEO of Fortelus Capital Management, a London-based, multi-billion dollar investment manager focused on European special situation investments. Prior to founding Fortelus in 2006, Mr. Babich was a Member of the General Partner at Silver Point Capital, a Greenwich, CT-based special situations fund. He joined Silver Point’s founder in early 2001 after the founder retired as head of Goldman Sachs’ Global Special Situations Group. As the first employee of Silver Point, Mr. Babich initially invested the founder’s capital, helping launch the fund in January 2002. He was asked to relocate to London to set up a European business in 2004, where he hired and built-out a team of 10 investment professionals. Mr. Babich graduated from the University of Pennsylvania in 1999, summa cum laude, with undergraduate degrees from Wharton and Engineering (Computer Sciences) as part of the Management & Technology (M&T) dual degree program, along with an MBA from Wharton. He currently serves as Chairman of the Board for the M&T program.

Jacob Doft, Chairman


Jacob Doft serves as Chairman of our board of directors. In 1995, Mr. Doft co-founded Highline Capital Management, L.P., a New York-based investment management firm (“Highline”), where he currently serves as Chief Executive Officer. Highline focuses on complex long and short investment opportunities in the public and private equity markets. Before co-founding Highline, Mr. Doft worked at Gleacher and Co., Inc. where his time was predominantly spent helping firms consider strategic mergers, acquisitions, and restructurings. Mr. Doft received a B.S. from Wharton School and an M.B.A. from Harvard Business School. He currently serves as a member of the Wharton Undergraduate Executive Board.

Lance Hirt, Director


Lance Hirt serves on our board of directors. Mr. Hirt has over 28 years in mergers and acquisitions, private equity, capital management, corporate governance, management consulting, and legal experience. He currently serves as a Managing Partner at Stonecourt, a New York based private investment firm. Previously, he spent 13 years in private equity as a partner at Lindsay Goldberg LLC, during which time the firm invested $10 billion of equity capital across 35 portfolio companies. Prior to that, he was a Managing Director in the mergers and acquisitions (“M&A”) department at Morgan Stanley, where he also served as the Operating Officer for the global M&A Division. Mr. Hirt began his career as a management consultant at Touche Ross & Co. and subsequently practiced law at Sullivan & Cromwell. Mr. Hirt has served on the board of directors of 19 portfolio companies during his 17-year private equity career. His investment experience spans a broad set of industries and geographies. Mr. Hirt graduated from Yeshiva College with a B.A. in Economics and received an M.B.A. from Harvard Business School and a Juris Doctorate from Harvard Law School. Mr. Hirt currently serves as a Trustee of Yeshiva University.

Andrew Rechtschaffen, Director


Andrew Rechtschaffen serves on our board of directors. Mr. Rechtschaffen is the Founder and Chief Executive Officer of AREX Capital Management, LP (“AREX”), an equities-focused investment firm with an opportunistic approach concentrated in three strategies: activism, catalyst-driven, and special situations. Prior to AREX, Mr. Rechtschaffen was a Partner at Greenlight Capital where he was a member of the investment team from 2002 to 2005 and 2011 to 2017, becoming a Partner in 2005 and again in 2014. Between these periods, he was a Managing Director at Citadel Investment Group managing a multi-billion-dollar portfolio in the Principal Strategies Group and the founder of Obrem Capital Management. He began his career as an Associate in Morgan Stanley’s Investment Banking Division. Mr. Rechtschaffen has served as director of Fiesta Restaurant Group, Inc. (Nasdaq: FRGI) since 2020 and currently serves as a director of the Wharton Alumni Executive Board. Mr. Rechtschaffen was awarded the Alan C. Greenberg Young Leadership Award by UJA-Federation of New York, Wall Street & Financial Services Division. Mr. Rechtschaffen graduated from the Wharton School at the University of Pennsylvania, summa cum laude, with a Bachelor of Science degree and an MBA.

Brett Barth, Director


Brett Barth has agreed to serve on our board of directors. Mr. Barth co-founded BBR Partners in 2000 and is a Co-Chief Executive Officer, co-managing the firm and overseeing BBR’s investment approach and implementation. He has extensive experience vetting investment opportunities across the asset class spectrum and through a range of market environments, working with both traditional and alternative investment managers. Mr. Barth is also a member of BBR’s Executive Committee and Investment Committee. Prior to founding BBR, Mr. Barth was in the Equities Division of Goldman Sachs. Previously, he served in Goldman’s Equity Capital Markets groups in New York and Hong Kong. He began his career in Goldman Sachs’ Corporate Finance Department. Mr. Barth has served a s a director of Cowen Inc. since June 2018. Mr. Barth is a trustee of the University of Pennsylvania as well as a member of the Board of Overseers of the Graduate School of Education. He previously served as both the Chair of the Penn Fund, the University of Pennsylvania’s undergraduate annual giving program, and as the Inaugural Chair of the Undergraduate Financial Aid Leadership Council. Mr. Barth is a member of the board and executive committee of the UJA-Federation of New York, he co-chairs the Annual Campaign and he serves on the endowment’s Investment Committee. Mr. Barth was awarded the Alan C. Greenberg Young Leadership Award by UJA-Federation of New York, Wall Street & Financial Services Division. Mr. Barth graduated summa cum laude with concentrations in Finance and Accounting from the Wharton School of the University of Pennsylvania. We believe Mr. Barth is well qualified to serve on our board of directors due to his extensive investment and wealth management expertise.

Lloyd Dean, Director


Lloyd Dean has agreed to serve on our board of directors. Mr. Dean has served as Chief Executive Officer of CommonSpirit Health, one of the nation’s largest non-profit healthcare systems, since February 2019 when CommonSpirit Health merged with Dignity Health, where Mr. Dean served Chief Executive Officer since June 2000. Prior to that, Mr. Dean served as Chief Operating Officer of Advocate Health Care, a healthcare organization, from 1997 to 2000. Mr. Dean has served on the board of directors of McDonald’s Corporation since 2015 and previously served on the boards of Navigant Consulting, Inc., Wells Fargo & Company, the Bar Area Council, the Catholic Health Association of the U.S., Mercy Housing California, and Cytori Therapeutics. Mr. Dean is Co-Chair of the California Future Health Workforce Commission, an organization composed of senior leaders from California’s leading health philanthropies. In 2019, California Governor Gavin Newsom appointed Mr. Dean to his Task Force on Business and Jobs Recovery, and he is the Board Chair for the Committee on Jobs, an organization that brings employment to the San Francisco Bay Area. We believe Mr. Dean is well qualified to serve on our board of directors due to his leadership, management, healthcare and strategic experience, including service on public company boards of directors.

Jack D. Hidary, Director


Jack D. Hidary has agreed to serve on our board of directors. Mr. Hidary is a serial technology entrepreneur and author. Mr. Hidary established the Hidary Foundation, which supports breakthroughs in oncology, and was recognized as a Global Leader of Tomorrow at the World Economic Forum in Davos. He served as Chairman and Co-Founder of Vista Research, an independent financial research company, from 2001 until its acquisition in 2005 by Standard & Poor’s. In 1995, Mr. Hidary co-founded the IT portal EarthWeb, and served as its Chairman and Chief Executive Officer through its initial public offering in 1998. Mr. Hidary serves on several private company boards, including as Chairman of Radimmune, a biotech company, and Mr. Hidary studied at Columbia University and received the Stanley Fellowship in Clinical Neuroscience at The National Institutes of Health, where he worked on the application of neural networks to medical imaging. We believe Mr. Hidary is well qualified to serve on our board of directors due to his experience as an entrepreneur, public company chief executive officer and service on boards of directors.

Steven Klosk, Director


Steven Klosk has agreed to serve on our board of directors. Mr. Klosk has served as a director of Cambrex Corporation (formerly NYSE: CBM), a leading global small molecule contract development and manufacturing organization (“Cambrex”), since 2008, and served as its President and Chief Executive Officer from 2008 until its acquisition by Permira in December 2019. Having joined Cambrex in 1992, Mr. Klosk held positions of increasing responsibility, including Executive Vice President, Administration, through 2005, when he assumed direct responsibility for the leadership of the Biopharmaceutical Business Unit as Chief Operating Officer. In August 2006, Mr. Klosk assumed the responsibility of the Pharma business as Executive Vice President and Chief Operating Officer – Biopharma & Pharma, and in February 2007 was appointed to Executive Vice President, Chief Operating Officer and President, Pharmaceutical Products and Services, the last role he held prior to being appointed President and Chief Executive Officer. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School. Mr. Klosk has served on the board of directors of Caladrius Biosciences, Inc. (Nasdaq: CLBS) since 2014. We believe Mr. Klosk is well qualified to serve on our board of directors due to his diversified management experience, particularly in the biopharmaceutical field.

Governance Documents